← All trials
NCT01882179
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2013
- Primary completion
- May 1, 2016
- Completion date
- May 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 61
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of LondonLead sponsor
- Basildon and Thurrock University Hospitals NHS Foundation TrustOverall official - principal investigator
- University of LondonOverall official - principal investigator
- University of LeedsOverall official - principal investigator
- University of LondonStudy director
- University of LondonStudy chair
- British Heart FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.